Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics reports developments as a clinical-stage biotechnology company developing immunology therapies for autoimmune and chronic inflammatory diseases. Company news centers on rezpegaldesleukin, also known as REZPEG or NKTR-358, a regulatory T cell stimulator evaluated across disease areas including atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
Recurring updates also cover Nektar's preclinical pipeline, including TNFR2 antibody and bispecific programs NKTR-0165 and NKTR-0166, and the modified hematopoietic colony stimulating factor protein NKTR-422. Financial results, public equity offerings, shelf-registration activity, employee inducement grants, and other capital and governance actions are regular news themes for NKTR.
Nektar Therapeutics (NKTR) reported Q2 2020 revenue of $48.8 million, significantly up from $23.3 million in Q2 2019, driven by a milestone payment of $25 million from Bristol-Myers Squibb. Cash and investments stood at $1.2 billion, down from $1.6 billion at year-end 2019 due to debt repayment. The net loss for Q2 was $80 million, or $0.45 per share, improving from a loss of $110.3 million in Q2 2019. The company has 5 ongoing registrational trials, with positive developments in immunotherapy and ongoing patient enrollment for NKTR-358 in lupus patients.
Nektar Therapeutics (Nasdaq: NKTR) will announce its second quarter 2020 financial results on August 6, 2020, post-market. CEO Howard Robin will lead a conference call at 5:00 PM ET to discuss the results. Interested parties can access the press release and a live audio-only webcast on Nektar's website. The replay of the call will be available until September 1, 2020. Nektar Therapeutics specializes in biopharmaceuticals, focusing on oncology and immunology.